GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Grand Pharmaceutical Group Ltd (FRA:MX6A) » Definitions » EV-to-EBITDA

Grand Pharmaceutical Group (FRA:MX6A) EV-to-EBITDA : 9.71 (As of Jun. 01, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Grand Pharmaceutical Group EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Grand Pharmaceutical Group's enterprise value is €3,543 Mil. Grand Pharmaceutical Group's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 was €365 Mil. Therefore, Grand Pharmaceutical Group's EV-to-EBITDA for today is 9.71.

The historical rank and industry rank for Grand Pharmaceutical Group's EV-to-EBITDA or its related term are showing as below:

FRA:MX6A' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4   Med: 9.71   Max: 18.54
Current: 10.42

During the past 13 years, the highest EV-to-EBITDA of Grand Pharmaceutical Group was 18.54. The lowest was 4.00. And the median was 9.71.

FRA:MX6A's EV-to-EBITDA is ranked better than
62.18% of 735 companies
in the Drug Manufacturers industry
Industry Median: 14.08 vs FRA:MX6A: 10.42

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2025-06-01), Grand Pharmaceutical Group's stock price is €0.95. Grand Pharmaceutical Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was €0.085. Therefore, Grand Pharmaceutical Group's PE Ratio (TTM) for today is 11.18.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


Grand Pharmaceutical Group EV-to-EBITDA Historical Data

The historical data trend for Grand Pharmaceutical Group's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Grand Pharmaceutical Group EV-to-EBITDA Chart

Grand Pharmaceutical Group Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.80 7.38 6.03 5.22 5.10

Grand Pharmaceutical Group Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.03 - 5.22 - 5.10

Competitive Comparison of Grand Pharmaceutical Group's EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Grand Pharmaceutical Group's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Grand Pharmaceutical Group's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Grand Pharmaceutical Group's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Grand Pharmaceutical Group's EV-to-EBITDA falls into.


;
;

Grand Pharmaceutical Group EV-to-EBITDA Calculation

Grand Pharmaceutical Group's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=3543.211/365.081
=9.71

Grand Pharmaceutical Group's current Enterprise Value is €3,543 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Grand Pharmaceutical Group's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 was €365 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Grand Pharmaceutical Group  (FRA:MX6A) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Grand Pharmaceutical Group's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.95/0.085
=11.18

Grand Pharmaceutical Group's share price for today is €0.95.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Grand Pharmaceutical Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was €0.085.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


Grand Pharmaceutical Group EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Grand Pharmaceutical Group's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Grand Pharmaceutical Group Business Description

Traded in Other Exchanges
Address
99 Queen's Road, Units 3302, 33rd Floor, The Center, Central, Hong Kong, HKG
Grand Pharmaceutical Group Ltd, is an international pharmaceutical company of technological innovation. Its core businesses cover three areas: nuclear medicine anti-tumor diagnosis and treatment, cerebro-cardiovascular precision interventional diagnosis and treatment technology, pharmaceutical technology, and biotechnology. Based on the pharmaceutical and biological industries, the Group focuses on the needs of patients, and technological innovation as the driving force Geographically, it derives a majority of its revenue from the PRC and also has a presence in America; Europe; and Asia other than the PRC, and others.

Grand Pharmaceutical Group Headlines

No Headlines